ETC-1002 regulatory update

Esperion said FDA lifted a partial clinical hold on ETC-1002, which is in Phase II testing to treat hypercholesterolemia. FDA placed the hold on ETC-1002 in 2009 after it deemed the compound a potential peroxisome proliferator-activated receptor (PPAR) agonist based on early findings in rodents. The partial hold prevented Esperion from conducting human trials longer than 6 months until the company completed a 2-year carcinogenicity study in rodents. ...